Search clinical trials for: Viral Protease Inhibitors

Total 64943 results

Pfizer

Completed

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

HIV Infection

United States, Canada
Abbott

Completed

The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

Australia
Stanford University

Completed

A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

HIV Infections

United States
Hoffmann-La Roche

Completed

Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients

HIV Infections

United States, Canada, Puerto Rico
Hoffmann-La Roche

Completed

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

HIV Infections

United States
Hoffmann-La Roche

Completed

The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs

HIV Infections

United States
The HIV Netherlands Australia Thailand Research...
Roche Pharma AG; Ministry of Health, Thailand

Completed

Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity

IDV Associated Nephrotoxicity

Thailand
Hoffmann-La Roche

Completed

A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients

HIV Infections

United States
Agouron Pharmaceuticals

Completed

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

HIV Infections

United States, Puerto Rico
Rodwick, Barry M., M.D.
Abbott

Terminated

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc (PALM)

HIV Infections | Acquired Immunodeficiency Syndrome

United States
Northwestern University
Pfizer; Tibotec, Inc

Completed

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 (MIDAS)

HIV Infections | HIV-1 Infection

United States
ViiV Healthcare
Pfizer

Completed

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Healthy

Belgium
ViiV Healthcare
Pfizer

Terminated

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Healthy

Singapore
University of British Columbia
Gilead Sciences

Completed

Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (QuaDar)

HIV Infection

Canada
Centre de Recherches et d'Etude sur la Pathologie...

Completed

Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection. (RADAR)

HIV Infections | HIV-1 Infection

France
Concert Pharmaceuticals

Completed

Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

Healthy Volunteers
Tibotec Pharmaceuticals, Ireland

Completed

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

HIV-1
The Rogosin Institute
Weill Medical College of Cornell University

Withdrawn

Velcade for Proliferative Lupus Nephritis

Proteinuria | Lupus Nephritis | Hematuria

United States
Centers for Disease Control and Prevention
US Department of Veterans Affairs

Completed

TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB

HIV Infections | Tuberculosis

United States, Canada
Glaxo Wellcome

Completed

A Study of Amprenavir in HIV-Infected Patients

HIV Infections

United States
Glaxo Wellcome

Completed

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

HIV Infections

United States
National Institutes of Health Clinical Center (CC)

Completed

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

Healthy Volunteers

United States
Abramson Cancer Center at Penn Medicine

Completed

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

United States
Swiss Group for Clinical Cancer Research

Completed

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Mature T-cell and Nk-cell Neoplasms

Switzerland
ANRS, Emerging Infectious Diseases

Completed

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients (DARULIGHT)

HIV INFECTION

France
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

HIV

United Kingdom, Germany, Denmark, Belgium, Austria, Poland, Australia, Russian Federation
Northwestern University
Bristol-Myers Squibb

Completed

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study (SABAR)

HIV Infection | Hyperlipidemia

United States, Argentina, Italy
Glaxo Wellcome

Completed

A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications

HIV Infections

United States
Fundación Huésped
Pfizer

Unknown

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

AIDS | HIV-1 Adults Patients | Triple Class Failure

Argentina
Stanford University
Pfizer

Completed

Paxlovid for Treatment of Long Covid (STOP-PASC)

Long COVID | Post-acute Sequelae of SARS-CoV-2 Infection

United States
Pfizer

Completed

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

COVID-19

United States, Korea, Republic of, Russian Federation, Czechia, Turkey, Malaysia, South Africa, Bulgaria, Poland, Hungary, Argentina, Brazil, Colombia, Japan, Mexico, Puerto Rico, Spain, Thailand, Ukraine, India
R-Pharm
Almedis; Scientific Center EFiS; ChromSystemsLab

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis c Genotype 1

Russian Federation
Pfizer

Completed

A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.

Healthy Participants

China
Boehringer Ingelheim

Approved for marketing

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

HIV Infections

United States
Hoffmann-La Roche

Completed

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Healthy Volunteer

Slovakia, United States, Czech Republic
Oswaldo Cruz Foundation
Abbott

Completed

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin (A06-295)

HIV Infection | Tuberculosis

Brazil
Saint Michael's Medical Center
Hoffmann-La Roche

Completed

Directly Observed Therapy in High Risk Populations in Newark, NJ

HIV Infections | Directly Observed Therapy

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

HIV Infections

United States
Hospital Clinic of Barcelona

Completed

Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients. (RALDAR)

Integrase Inhibitors, HIV; HIV PROTEASE INHIB

Spain
R-Pharm
Ascent

Completed

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Hepatic Impairment

Georgia, Russian Federation
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Ritonavir

Healthy

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

Healthy

United States
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
ViiV Healthcare

Completed

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

HIV Infection | Infection, Human Immunodeficiency Virus I

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

HIV Infections | HIV-1

United States, France, Spain, Canada, South Africa, Argentina, Brazil, Romania
Triangle Pharmaceuticals

Completed

A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive

HIV Infections

United States
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital; First People's Hospital of Lin'an District; First People...

Recruiting

Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

Hospitalized Patients

China
Novartis Pharmaceuticals

Completed

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients (CBZF961X2201)

Hepatitis C

United States
Huoshenshan Hospital
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

COVID-19

China

3

Subscribe